Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTV0YFR)

• DTT Name: Lipid peroxidation (LPO)
• Gene Name: LPO
• DTT Type: Clinical trial target; [1]
• UniProt ID: NOUNIPROTAC
• TTD ID: T15784

Molecular Interaction Atlas (MIA) of This DTT

2 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RAXOFELAST	DMK2E0N	Ischemia	8B10-8B11	Phase 2	[2]
T-817MA	DMD72F4	Alzheimer disease	8A20	Phase 2	[1]

2 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TAK-218	DM7S69Q	Neurological disorder	6B60	Discontinued in Phase 2	[3]
U-104067F	DMC94D2	Neurological disorder	6B60	Discontinued in Phase 1	[4]

1 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
G009	DMXZGKI	Immune System disease	4A01-4B41	Investigative	[5]

References

• [1] A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. Neuropharmacology. 2008 Oct;55(5):654-60.
• [2] Lipid peroxidation inhibition by raxofelast improves angiogenesis and wound healing in experimental burn wounds. Shock. 2005 Jul;24(1):85-91.
• [3] ESR study on the antioxidant activity of TAK-218 in biological model membranes. Chem Pharm Bull (Tokyo). 2000 Jun;48(6):784-92.
• [4] Two novel pyrrolopyrimidine lipid peroxidation inhibitors U-101033E and U-104067F protect facial motor neurons following neonatal axotomy. Exp Neurol. 1996 Oct;141(2):304-9.
• [5] Inhibition of lipid peroxidation and oxidative DNA damage by Ganoderma lucidum. Phytother Res. 2001 May;15(3):245-9.